下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Asian ADRs Move Slightly Lower in Monday Trading
亚洲ADR周一小幅走低

MT Newswires ·  {{timeTz}}

10:33 AM EDT, 08/08/2022 (MT Newswires) -- American depositary receipts of Asian stocks were trading 0.1% lower at 1,530.33 on the S&P/BNY Mellon Asia 50 ADR Index on Monday.

美国东部时间2022年8月8日上午10点33分--亚洲股票的美国存托凭证周一在S&P/BNY Mellon Asia 50 ADR指数中下跌0.1%,至1,530.33点。

In North Asia, the gainers were led by solar project developer ReneSola (SOL) and financial product information provider Jianpu Technology (JT), which rose 6.2% and 5.6%, respectively. They were followed by online video game operator The9 Ltd. (NCTY) and biotech firm Zai Lab (ZLAB), which were up 5.3% and 5.2%, respectively.

在北亚,涨幅居前的是太阳能项目开发商瑞能新能源(Sol)和金融产品信息提供商简普科技(JT),它们分别上涨6.2%和5.6%。紧随其后的是网络游戏运营商第九城市和生物科技公司再鼎医药-SB,涨幅分别为5.3%和5.2%。

The decliners in North Asia were led by real estate services provider Leju Holdings (LEJU) and educational services provider Four Seasons Education (FEDU), which declined 18% and 6.5%, respectively. They were followed by fintech platform Jiayin Group (JFIN) and content aggregator Qutoutiao (QTT), which lost 2% and 1.9%, respectively.

北亚地区跌幅最大的是房地产服务提供商乐居(Leju)和教育服务提供商四季教育(FEDU),它们分别下跌了18%和6.5%。紧随其后的是金融科技平台嘉银金科集团(JFIN)和内容聚合器趣头条(QTT),分别下跌2%和1.9%。

In South Asia, the gainers were led by IT company Sify Technologies (SIFY) and biotech firm ASLAN Pharmaceuticals (ASLN), which rose 4.3% and 3.7%, respectively. They were followed by automaker Tata Motors (TTM) and digital entertainment company Sea (SE), which added 1.6% and 1.4%, respectively.

在南亚,涨幅最大的是IT公司Sify Technologies(SIFY)和生物科技公司Aslan PharmPharmticals(ASLN),分别上涨4.3%和3.7%。紧随其后的是汽车制造商塔塔汽车(Tata Motors)和数字娱乐公司Sea,分别上涨1.6%和1.4%。

The lone decliner in South Asia was IT company Wipro Limited (WIT), which was off 0.6%.

南亚股市唯一下跌的是IT公司Wipro Limited(WIT),下跌0.6%。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部